Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Not Available].

Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege·2018

Same author

[Health problems and problems in the health care system in China: impressions of a physician after 6 China trips].

Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege·2015

Same author

[Letter on issue 11/14 introduction. "Social freezing"].

Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege·2015

Same author

[Ethical problems in planning therapy studies].

Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege·2013

Same author

[Great hopes, bitter loss].

Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege·2011

Same author

[Baby drop and anonymous delivery - are they an answer?].

Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege·2010

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Gynecologic oncology: the German view.

Jörg Baltzer¹

¹prof.baltzer@the-krefelder.de

Archives of Gynecology and Obstetrics

|February 1, 2008

Summary

Gynecologic oncology faces challenges with aging populations and increased breast and vulvar cancers. Treatment for elderly patients should be individualized based on comorbidity, with lymph node evaluation crucial for determining adjuvant therapy needs.

Area of Science:

Gynecologic Oncology
Geriatric Oncology
Cancer Epidemiology

Background:

Increasing incidence of elderly patients in gynecologic oncology.
Rising rates of breast and vulvar cancers correlate with aging demographics.
Need for individualized, multidisciplinary treatment approaches.

Purpose of the Study:

To outline diagnostic and therapeutic strategies for elderly gynecologic cancer patients.
To emphasize individualized treatment based on comorbidity.
To clarify nodal status assessment and adjuvant therapy decisions.

Main Methods:

Literature review and clinical experience.
Adaptation of standard diagnostic and therapeutic efforts for elderly patients, considering comorbidities.

More Related Videos

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Focus on breast-conserving therapy for elderly breast cancer patients.

Individualized therapy for vulvar cancer.

Systematic lymph node dissection for endometrial cancer.

Main Results:

Treatment modifications for elderly patients should primarily address comorbidity.
Breast-conserving therapy is a viable option for elderly breast cancer patients.
Accurate nodal status determination relies on surgical removal and histologic evaluation, not intraoperative frozen section depth of invasion.
Adjuvant radiotherapy can be avoided in lymph node-negative patients.

Conclusions:

Individualized treatment plans are essential for elderly gynecologic cancer patients.
Histologic evaluation of surgically removed lymph nodes is critical for accurate staging.
Adjuvant radiotherapy is often unnecessary for lymph node-negative patients, preventing potential toxicity.